Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) launched a public, near real-time real-world data dashboard for its iLet Bionic Pancreas at betabionics.com/hcp/real-world-data.
The dashboard shows outcomes for all iLet users meeting two criteria: provider-reported baseline HbA1c and at least two weeks of cloud-uploaded data, with no exclusions, plus a companion guide to help clinicians evaluate AID system data.
Positive
- None.
Negative
- None.
News Market Reaction – BBNX
In the Jun 2 session, BBNX declined 0.08%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Mint timeline update | Positive | +11.4% | Pushed Mint commercialization target to end Q2 2027 with manufacturing progress. |
| Apr 27 | Conference appearance | Neutral | -5.3% | Announcement of presentation slot at Bank of America health care conference. |
| Apr 21 | Q1 results, guidance | Positive | -4.4% | Reported higher Q1 sales and gross margin and raised full-year 2026 guidance. |
| Mar 31 | Feature launch | Positive | +1.6% | Launched Bionic Insights to structure iLet data into actionable clinical categories. |
| Mar 30 | Earnings date notice | Neutral | +1.6% | Scheduled Q1 2026 results release and conference call with webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Product and platform updates (iLet features, Mint commercialization, Bionic Insights) have often coincided with positive moves, while strong earnings and conference news have previously seen negative or mixed price reactions.
Over the last few months, Beta Bionics has focused on commercial and product execution. On Mar 31, it launched Bionic Insights to enhance clinical data use, and on May 21 it updated the Mint™ commercialization timeline to full launch by end of Q2 2027, which saw a +11.4% move. Earnings on Apr 21 featured higher guidance but were followed by a -4.4% reaction. Today’s real-world iLet data release continues the theme of data-driven product positioning.
Key Terms
automated insulin delivery medical
real-world data medical
hba1c medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New dashboard at betabionics.com shows every patient, every baseline, every outcome, with no filters and no fine print
IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is now publicly available at betabionics.com/hcp/real-world-data. The dashboard publishes outcomes for
Real-world data is a key reference point for clinicians weighing multiple automated insulin delivery (AID) options. Most of the evidence in the category arrives in batches: posters, abstracts, paragraphs in earnings releases. Beta Bionics is taking a different approach. The data is published continuously and openly, available to anyone who wants to evaluate the iLet on its real-world performance, including clinicians, researchers, payers, patients, and the broader diabetes community.
The Real-world data dashboard on Beta Bionics’ website is centered around six guiding principles that demonstrate the company’s data transparency alongside a companion guide for evaluating real-world data across AID systems. The guide prompts clinicians to consider sample size, baseline reporting, inclusion criteria, device settings, and time frame before comparing one study to another, helping providers interpret real-world claims from any manufacturer, including Beta Bionics.
“Healthcare providers shouldn’t have to take our word for it. They should be able to see the data for themselves, on demand,” said Sean Saint, President and Chief Executive Officer of Beta Bionics. “Two simple criteria. At least two weeks on the iLet, and we have your data. That's it. No exclusions. It’s time for data transparency in our industry. If we can do this, every company in our category can do this....and should!”
Beta Bionics is setting a new standard in the Automated Insulin Delivery category by making real-world data easy to evaluate and interpret with clearly stated criteria and no exclusions applied, rather than relying on selective populations or optimal performance. The company welcomes others in the industry to publish their real-world data with clear inclusion criteria and no fine print to make it easier for providers and patients to evaluate outcomes with confidence.
The dashboard launch comes ahead of the American Diabetes Association’s 86th Scientific Sessions in June, where Beta Bionics will host healthcare providers at its booth and reference the public dashboard in clinical conversations throughout the meeting.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
